???? ???????? *BIOCON 3Q EBITDA 7.87B RUPEES, EST. 8.4B RUPEES
A decent miss versus consensus, but the results themselves are solid. If we look at core EBITDA, quarterly figures were 4% higher YoY at INR10bn, with an operating margin of 26%. In the Biosimilars segment (58% of revenues), the company expects a "clear line of sight for multiple new product launches beginning in Q4FY25". Overall neutral for spreads.

Find more articles and bullets on these widgets:
WTI futures are trading higher today as the contract extends recent gains. A stronger reversal to the upside would refocus attention on key short-term resistance at $76.41, the Oct 8 high. Initial firm resistance is unchanged at $71.97. A bear threat in Gold remains present. The yellow metal traded sharply lower on Dec 18 and the move undermines a recent bull theme. A resumption of weakness would open key support at $2536.9, the Nov 14 low.